MeiraGTx Holdings PLC at Barclays Global Healthcare Conference Transcript
Good afternoon. My name is Gena Wang. I'm a SMID cap biotech analyst from Barclays. It is my great pleasure to introduce our next speaker, Zandy Forbes, Chief Executive Officer and the President of MeiraGTx.
Thank you, Gena, and thank you to Barclays for inviting me to speak about Meira today. I'll just bring your attention to our forward-looking statement and move on to an overview of the company.
We were formed just under 4 years ago as a private company with the aim of developing gene therapies to treat a multitude of different diseases, not just rare diseases but many different diseases in a cost-effective way. So in setting up the company, we established a number of things that is required for a gene therapy company in general. One of the first things that we took into the company on formation is forward-looking technology to be able to regulate transgenes. This is something that many groups have looked for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
